Planegg-Martinsried, Germany, 19 October 2023 – 4SC AG (4SC or “the Company”) (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today provided a business update for the three months ended 30 September 2023, as well as its current outlook. The full report is available […]